Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 6/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 6/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.83 |
| ▸ | SRC | P12931 | 7/20 | 0.82 |
| ▸ | FLT1 | P17948 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366761 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8135892 | 0.90 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8130155 | 0.86 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL22532383 | 0.85 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL29390330 | 0.85 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8130610 | 0.84 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8127464 | 0.83 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL30386897 | 0.82 | FGFR1 (0.69) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL31648262 | 0.82 | FGFR1 (0.76) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8130201 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112313327-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2024-04-19 | — | — | CN | claimed |
| US-20210254014-A1 | GROWTH INHIBITOR | KYOTO UNIVERSITY (JP) | 2021-08-19 | — | — | US | claimed |
| EP-3812456-A1 | GROWTH INHIBITOR | Kyoto University (JP) | 2021-04-28 | — | — | EP | claimed |
| CN-112313327-A | Proliferation inhibitor | 国立大学法人京都大学 | 2021-02-02 | — | — | CN | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4680255-A1 | METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | FGFR1 30/4885FGFR2 62/4885FGFR4 49/4885 |
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | FGFR1 797/4885FGFR2 1381/4885FGFR4 2414/4885 |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | PAX2, ZP1, ALDH1A2 | FGFR1 712/4885FGFR2 1293/4885FGFR4 1109/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | FGFR1 87/4885FGFR2 220/4885FGFR4 70/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | FGFR1 848/4885FGFR2 1173/4885FGFR4 1995/4885 |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | LGALS1, LGALS9, ALDH1A2 | FGFR1 499/4885FGFR2 1047/4885FGFR4 1593/4885 |
| US-20210254014-A1 | GROWTH INHIBITOR | MKI67, FGFR1, FGF2 | FGFR1 2/4885FGFR2 4/4885FGFR4 7/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | FGFR1 739/4885FGFR2 1138/4885FGFR4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.